Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

MIRA

Mira Pharmaceuticals Inc

May 02 • 04:00PM ET

0.8079

Dollar change -0.0114
Percentage change -1.39	%

Healthcare • Drug Manufacturers - General • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.81	Insider Own	33.99%	Shs Outstand	14.78M	Perf Week	-10.23%
Market Cap	11.94M	Forward P/E	-	EPS next Y	-0.32	Insider Trans	-4.52%	Shs Float	9.76M	Perf Month	-24.50%
Income	-11.98M	PEG	-	EPS next Q	-0.10	Inst Own	3.50%	Short Float	0.43%	Perf Quarter	-15.84%
Sales	0.00M	P/S	-	EPS this Y	39.06%	Inst Trans	-	Short Ratio	0.06	Perf Half Y	-58.36%
Book/sh	0.30	P/B	2.73	EPS next Y	17.95%	ROA	-	Short Interest	0.04M	Perf Year	-
Cash/sh	0.31	P/C	2.60	EPS next 5Y	-	ROE	-	52W Range	0.76 - 7.98	Perf YTD	-23.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-273.92%	52W High	-89.88%	Beta	-
Dividend TTM	-	Quick Ratio	8.70	Sales past 5Y	0.00%	Gross Margin	-	52W Low	6.30%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	8.70	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	35.23	Volatility	5.74% 7.08%
Employees	3	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-219.59%	Payout	-	Rel Volume	0.04	Prev Close	0.82
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	683.60K	Price	0.81
SMA20	-9.89%	SMA50	-22.27%	SMA200	-68.46%	Trades		Volume	24,062	Change	-1.39%

Apr-02-24 08:00AM	Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission (PR Newswire)
Apr-01-24 02:53PM	MIRA Stock Earnings: Mira Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
Mar-21-24 11:04AM	MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor (PR Newswire)
Mar-08-24 08:19AM	Why Is Mira Pharmaceuticals (MIRA) Stock Up 52% Today? (InvestorPlace) +65.28%
Feb-05-24 08:30AM	MIRA Pharmaceuticals Provides Corporate Update (PR Newswire) +45.99%
08:00AM	Loading…
Dec-04-23 08:00AM	MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations (PR Newswire) -5.26%
Nov-29-23 08:00AM	MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80% (PR Newswire)
Nov-21-23 10:42AM	MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time (PR Newswire) -16.13%
10:09AM	MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a (PR Newswire)
Nov-20-23 08:00AM	MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2 (PR Newswire) +40.06%
Oct-26-23 07:23AM	MIRA: Developing Cannabis with Benefits and Without Side Effects (Zacks) +5.38%
Sep-18-23 08:30AM	MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot (PR Newswire) +38.80%
Sep-05-23 08:31AM	MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts (PR Newswire)
Aug-31-23 08:31AM	MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit (PR Newswire)
Aug-29-23 11:39AM	MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time (PR Newswire)
09:35AM	Loading…
Aug-09-23 09:35AM	MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast (ACCESSWIRE)
Aug-03-23 02:40PM	MIRA Pharmaceuticals debuts on the Nasdaq with plans to revolutionize medicinal CBD and THC (News Direct)

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company engages in developing its product candidate, MIRA1a, as a synthetic cannabinoid analog for treating anxiety & chronic pain by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors. MIRA Pharmaceuticals was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McNulty Brian Patrick	10% Owner	Dec 11 '23	Sale	1.55	46,005	71,496	660,000	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Dec 08 '23	Sale	1.61	19,053	30,633	683,002	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Dec 07 '23	Sale	1.89	33,333	63,156	692,529	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Dec 06 '23	Sale	2.95	27,733	81,785	709,196	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Dec 04 '23	Sale	3.98	61,331	244,097	723,062	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Nov 30 '23	Sale	3.77	4,842	18,273	753,728	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Nov 29 '23	Sale	3.98	7,399	29,445	756,149	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Nov 28 '23	Sale	4.00	241	964	759,849	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Nov 27 '23	Sale	4.00	6,425	25,715	759,969	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Nov 21 '23	Sale	5.00	5,000	25,000	763,181	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Nov 20 '23	Sale	5.07	26,733	135,523	765,681	Dec 27 05:33 PM
Cappy George	10% Owner	Aug 07 '23	Buy	7.00	119,048	833,336	2,859,318	Aug 24 05:38 PM
Cappy George	10% Owner	Aug 02 '23	Buy	7.00	157,170	1,100,190	2,740,270	Aug 04 01:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MIRA

Mira Pharmaceuticals Inc

Upgrade your FINVIZ experience